IDEAYA Biosciences (IDYA) Projected to Post Quarterly Earnings on Tuesday

IDEAYA Biosciences (NASDAQ:IDYA) is anticipated to announce its earnings results before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of ($0.63) per share and revenue of $4.31 million for the quarter.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $22.42 on Tuesday. IDEAYA Biosciences has a 12 month low of $22.10 and a 12 month high of $47.74. The business’s 50-day moving average is $24.94 and its two-hundred day moving average is $30.52. The firm has a market capitalization of $1.94 billion, a PE ratio of -9.62 and a beta of 0.82.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. UBS Group started coverage on IDEAYA Biosciences in a research report on Thursday, October 24th. They set a “buy” rating and a $50.00 price target on the stock. Stephens began coverage on shares of IDEAYA Biosciences in a research note on Monday, November 18th. They issued an “overweight” rating and a $51.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $52.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Oppenheimer reissued an “outperform” rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Finally, Leerink Partners lowered IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.67.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.